Menu

1 / 2

ImmunityBio: Q3 ANKTIVA Slowdown And Cash Burn Reaffirm My Sell Rating

All Articles on Seeking Alpha·about 8 hours ago
#nwlQwgXu
#seekingalpha#investment#seeking#alpha#sell
Long article (465 words) — no AI summary yet.
Reading 0:00
15s threshold

Home

Healthcare

Summary

ImmunityBio remains a Sell: its $7 billion enterprise value overstates the present opportunity in bladder cancer.

ANKTIVA sales fell sequentially in Q3 despite prior NCCN coverage; papillary approval and automatic CMS coverage could test whether demand re-accelerates.

BCG-naïve bladder cancer is a major opportunity, but QUILT-2.005's positive topline results omitted critical response-rate details; broader pipeline expansion remains speculative.

With just over a year of cash runway at recent burn rates, IBRX faces going-concern and dilution risks as losses widen.

Dimas Aldrian/iStock via Getty Images

ImmunityBio Overview

I've been a bear on ImmunityBio ( IBRX ) for quite a while now. My last assessment on the stock was in August.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.